Thus, parallel studies utilizing mice and cell models harboring the AD and FTD risk mutations including the R47H, Y38C, and T66 M TREM2 mutants, in addition to cell specific floxed TREM2 models, will be critical to directly assess the role of TREM2 in modifying tauopathy. This evidence concerns the gene TREM2 and frontotemporal dementia.